Recent Posts
- Therapeutic Drug Monitoring in Psychiatry – Positive Impact on Patients through Lab-Clinician Collaboration
- Clinical Impact and Outcomes Utilizing Antipsychotic TDM
- Essential Antipsychotic Drug Level Monitoring
- Guidance for Managing the Unexpectedly High or Low Clozapine Level
- Health Canada Approves Saladax’s 5-Fluorouracil Chemotherapy Therapeutic Drug Monitoring (TDM) Test
-
Therapeutic Drug Monitoring in Psychiatry – Positive Impact on Patients through Lab-Clinician Collaboration September 27, 2024 - Clinical Impact and Outcomes Utilizing Antipsychotic TDM September 27, 2024
- Essential Antipsychotic Drug Level Monitoring July 8, 2024
- Guidance for Managing the Unexpectedly High or Low Clozapine Level July 8, 2024
-
Health Canada Approves Saladax’s 5-Fluorouracil Chemotherapy Therapeutic Drug Monitoring (TDM) Test June 5, 2024 - Practical Learnings and Knowledge When Implementing Rapid TDM Blood Levels May 6, 2024
-
Best Practices and Potential Barriers in Implementing Rapid Clozapine Levels September 27, 2023 -
Antipsychotic Blood Levels: LAI Strategies, Baselining, and Managing Non-Trough Situations July 4, 2023 -
Determining Clozapine Response vs. Nonresponse July 3, 2023 -
Using Rapid Clozapine Blood Levels to Improve Patient Management – 30 Years of Clozapine Experience July 2, 2023
